TY - JOUR
T1 - Tissue factor activity on microvesicles from cancer patients
AU - Ender, Fanny
AU - Freund, Annika
AU - Quecke, Tabea
AU - Steidel, Corinna
AU - Zamzow, Piet
AU - von Bubnoff, Nikolas
AU - Gieseler, Frank
N1 - Funding Information:
We thank Rajam Csordas for her excellent English editing. We thank Servier Medical Art (smart.servier.com) for providing tools for the graphical abstract. We thank Matthias Klinger and Hristo ?run for performing scanning electron microscopy.
Publisher Copyright:
© 2019, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Purpose: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown high expression variability. As a contribution to this discussion, we present a study investigating plasma samples from patients with various progressive tumors at high risk for VTE. Methods: Based on our previous study uncovering microvesicles (MVs), the larger ectosome-like extracellular vesicles (EV), as the major source of TF activity in EV preparations, we now determined TF activity on enriched MVs isolated from plasma of cancer patients and compared it with that on MVs from healthy individuals. Results: We found considerably higher amounts of MVs as well as higher levels of MV-bound TF activities in the plasma of cancer patients. We also show that preparations from plasma of cancer patients have the potency to induce ERK phosphorylation in a human tumor cell line through proteinase-activated receptor two (PAR2) activation. Conclusion: We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE. Graphic abstract: [Figure not available: see fulltext.].
AB - Purpose: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown high expression variability. As a contribution to this discussion, we present a study investigating plasma samples from patients with various progressive tumors at high risk for VTE. Methods: Based on our previous study uncovering microvesicles (MVs), the larger ectosome-like extracellular vesicles (EV), as the major source of TF activity in EV preparations, we now determined TF activity on enriched MVs isolated from plasma of cancer patients and compared it with that on MVs from healthy individuals. Results: We found considerably higher amounts of MVs as well as higher levels of MV-bound TF activities in the plasma of cancer patients. We also show that preparations from plasma of cancer patients have the potency to induce ERK phosphorylation in a human tumor cell line through proteinase-activated receptor two (PAR2) activation. Conclusion: We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE. Graphic abstract: [Figure not available: see fulltext.].
UR - http://www.scopus.com/inward/record.url?scp=85075422691&partnerID=8YFLogxK
U2 - 10.1007/s00432-019-03073-0
DO - 10.1007/s00432-019-03073-0
M3 - Journal articles
C2 - 31734835
AN - SCOPUS:85075422691
SN - 0171-5216
VL - 146
SP - 467
EP - 475
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 2
ER -